Immunovant
Quarterly Financials
| Values in thousands | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
Revenue | $7,095 | $0 | $0 | $0 |
Gross Profit | 7,095 | -101 | -105 | |
EBITDA | -153,132 | -150,604 | -108,982 | -125,803 |
EBIT | -153,224 | -150,700 | -109,083 | -125,908 |
Net Income | -153,224 | -147,856 | -110,635 | -126,502 |
Net Change In Cash | 7,095 | 0 | 0 | 0 |
Free Cash Flow | -124,405 | -95,067 | -92,325 | -102,515 |
Cash | 797,798 | 902,110 | 994,525 | 521,870 |
Basic Shares | 205,545 | 203,709 | 181,513 | 173,643 |
Annual Financials
| Values in thousands | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
Gross Profit | -409 | -377 | -231 | -1,324 |
EBITDA | -504,982 | -412,572 | -258,538 | -198,276 |
EBIT | -505,391 | -412,949 | -258,769 | -198,469 |
Net Income | -505,606 | -413,840 | -259,336 | -210,960 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Cost of Revenue | -117,505 | |||
Free Cash Flow | -407,318 | -376,633 | -214,587 | -188,390 |
Cash | 902,110 | 713,971 | 635,365 | 376,532 |
Basic Shares | 182,421 | 151,574 | 138,100 | 123,075 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-06-30 | -$0.75 |
2026-03-31 | -$0.67 |
2025-12-31 | -$0.54 |
2025-09-30 | -$0.65 |